甲基泼尼松龙治疗的多发性硬化症患者外周血单个核细胞与内皮细胞的黏附性降低：初步结果

Reduced adhesion of PBMNCs to endothelium in methylprednisolone-treated MS patients: preliminary results.

作者信息

Gelati M, Corsini E, Dufour A, Ciusani E, Massa G, Frigerio S, Milanese C, Nespolo A, Salmaggi A

机构信息

Istituto Nazionale Neurologico C. Besta, Milan, Italy.

出版信息

Acta Neurol Scand. 1997 Nov;96(5):283-92. doi: 10.1111/j.1600-0404.1997.tb00285.x.

DOI:10.1111/j.1600-0404.1997.tb00285.x

PMID:9404997

Abstract

Methylprednisolone (MP) is a synthetic steroid commonly used in the treatment of multiple sclerosis (MS) relapses. It has a wide spectrum of activities on immune cells: it might also act by preventing mononuclear cell/endothelium adhesion. We studied adhesion phenomena between cultured human umbilical vein endothelial cells (HUVECs) and PBMNCs (CD45+, CD14+) from 6 MS patients treated in vivo with MP. We also studied fluctuations in CD11a and CD18 levels on lymphocytes and monocytes, as well as changes in serum sICAM-1 and sVCAM-1 concentrations. After MP treatment, PBMNCs adhesion to endothelium decreased at 3 h, while it went back to baseline levels at 24 h. A tendency to increase in both CD11a and CD18 on the surface of lymphocytes was detected, while an increase in serum sVCAM-1 was seen at 3 h.

摘要

甲基泼尼松龙（MP）是一种常用于治疗多发性硬化症（MS）复发的合成类固醇。它对免疫细胞具有广泛的活性：它也可能通过阻止单核细胞/内皮细胞粘附起作用。我们研究了用MP进行体内治疗的6例MS患者的培养人脐静脉内皮细胞（HUVEC）与外周血单核细胞（PBMNC，CD45 +，CD14 +）之间的粘附现象。我们还研究了淋巴细胞和单核细胞上CD11a和CD18水平的波动，以及血清可溶性细胞间粘附分子-1（sICAM-1）和可溶性血管细胞粘附分子-1（sVCAM-1）浓度的变化。MP治疗后，PBMNC与内皮细胞的粘附在3小时时降低，而在24小时时恢复到基线水平。检测到淋巴细胞表面的CD11a和CD18均有增加的趋势，而血清sVCAM-1在3小时时升高。